Next Article in Journal
Untargeted Metabolomics Approach Correlated Enniatin B Mycotoxin Presence in Cereals with Kashin–Beck Disease Endemic Regions of China
Previous Article in Journal
Unveiling the Clinical Benefits of High-Volume Hemodiafiltration: Optimizing the Removal of Medium-Weight Uremic Toxins and Beyond
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Toxins
Volume 15
Issue 9
10.3390/toxins15090532
toxins-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

A UK Single-Center, Retrospective, Noninterventional Study of Clinical Outcomes and Costs of Two BotulinumtoxinA Treatments for Limb Spasticity

by
Clive Bezzina
1,*,
Vadim Degtiar
2,
Natalya Danchenko
3,†,
Pascal Maisonobe
3,
Benjamin Davis
3,†,
Emanuel Engmann
2,†,
Elodie Guyon
3,†,
Sophie Lecanuet
3 and
John Whalen
2,†
1
North Staffordshire Rehabilitation Centre, Haywood Hospital, Stoke-on-Trent ST6 7AG, UK
2
Ipsen, Slough SL1 3XE, UK
3
Ipsen, 92100 Boulogne-Billancourt, France
*
Author to whom correspondence should be addressed.
†
Employee of Ipsen at the time this research was conducted.
Toxins 2023, 15(9), 532; https://doi.org/10.3390/toxins15090532
Submission received: 18 July 2023 / Revised: 16 August 2023 / Accepted: 22 August 2023 / Published: 30 August 2023
Browse Figures
Versions Notes

Abstract

Service model changes at the North Staffordshire Rehabilitation Centre (UK) included switching spasticity treatment from onabotulinumtoxinA (onaBoNT-A) to abobotulinumtoxinA (aboBoNT-A). This noninterventional, retrospective, longitudinal study (NCT04396704) describes the clinical and economic outcomes in toxin-naive adults with spasticity who received onaBoNT-A (Cohort 1; 2015–2017) or aboBoNT-A (Cohort 2; 2017–2019). Outcomes included Goal Attainment Scale T (GAS-T) score, treatment satisfaction, quality of life (QoL; EQ-5D visual analog scale [VAS] score), and treatment costs. Adverse events were recorded for Cohort 2. Cohort 1 included 60 patients (mean [standard deviation] dose, 206.0 [98.8] U); Cohort 2 included 54 patients (753.7 [457.3] U). Mean (95% confidence interval) GAS-T scores for Cohorts 1 and 2 were 43.1 (39.3–46.9) and 47.8 (43.7–51.9) at Week 6, and 43.2 and 44.3 at Week 12, respectively. In both cohorts most patients were satisfied with treatment. At Week 12, QoL had not changed in Cohort 1 but had improved in Cohort 2 (EQ-5D VAS, −5). Mean estimated per-patient costs (in 2021) for Cohorts 1 and 2 were £315.56 and £249.25, respectively, at Week 6, and £343.20 and £273.21, respectively, at Week 12. Fifteen non–treatment-related serious adverse events and two deaths were recorded. These data may warrant a larger prospective study powered to compare outcomes of aboBoNT-A and onaBoNT-A.
Keywords: adult limb spasticity; stroke; botulinumtoxinA; abobotulinumtoxinA; aboBoNT-A; clinical practice; healthcare cost; onabotulinumtoxinA; onaBoNT-A; rehabilitation adult limb spasticity; stroke; botulinumtoxinA; abobotulinumtoxinA; aboBoNT-A; clinical practice; healthcare cost; onabotulinumtoxinA; onaBoNT-A; rehabilitation

Share and Cite

MDPI and ACS Style

Bezzina, C.; Degtiar, V.; Danchenko, N.; Maisonobe, P.; Davis, B.; Engmann, E.; Guyon, E.; Lecanuet, S.; Whalen, J. A UK Single-Center, Retrospective, Noninterventional Study of Clinical Outcomes and Costs of Two BotulinumtoxinA Treatments for Limb Spasticity. Toxins 2023, 15, 532. https://doi.org/10.3390/toxins15090532

AMA Style

Bezzina C, Degtiar V, Danchenko N, Maisonobe P, Davis B, Engmann E, Guyon E, Lecanuet S, Whalen J. A UK Single-Center, Retrospective, Noninterventional Study of Clinical Outcomes and Costs of Two BotulinumtoxinA Treatments for Limb Spasticity. Toxins. 2023; 15(9):532. https://doi.org/10.3390/toxins15090532

Chicago/Turabian Style

Bezzina, Clive, Vadim Degtiar, Natalya Danchenko, Pascal Maisonobe, Benjamin Davis, Emanuel Engmann, Elodie Guyon, Sophie Lecanuet, and John Whalen. 2023. "A UK Single-Center, Retrospective, Noninterventional Study of Clinical Outcomes and Costs of Two BotulinumtoxinA Treatments for Limb Spasticity" Toxins 15, no. 9: 532. https://doi.org/10.3390/toxins15090532

APA Style

Bezzina, C., Degtiar, V., Danchenko, N., Maisonobe, P., Davis, B., Engmann, E., Guyon, E., Lecanuet, S., & Whalen, J. (2023). A UK Single-Center, Retrospective, Noninterventional Study of Clinical Outcomes and Costs of Two BotulinumtoxinA Treatments for Limb Spasticity. Toxins, 15(9), 532. https://doi.org/10.3390/toxins15090532

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop